Can PET-CT with FDG replace contrast enhanced CT for imaging of liver metastases?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 12, 2007, Pages 1902-1905

  Strauss, Ludwig G ^a   Dimitrakopoulou Strauss, Antonia ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 DOPA F 18; ANTINEOPLASTIC AGENT; BOMBESIN GA 68; DOTATOC GA 68; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; GASTROINTESTINAL TUMOR; HUMAN; LIVER METASTASIS; MELANOMA; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROBABILITY; SENSITIVITY AND SPECIFICITY;

CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; LIVER NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36749078531     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0619-7     Document Type: Note

References (17)

1. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006;10:982-9.
2. Cancer. World Health Organization [February 2006]. Retrieved on 2007-05-24.
3. Colon Cancer, Adenocarcinoma. http://www.emedicine.com/med/topic413.htm
4. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumours: PET evaluation. Radiology 1989;170:329-32.
5. Minn H, Soini I. 18F-fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-6.
6. Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, et al. The impact of 18F-FDG PET-CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007; xx:xx-xx.
7. Wiering B, Krabbe PF, Jager GJ, Oyen WJG, Ruers TJM. The impact of fluor-18-deoxyglucose positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658-70.
8. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with F-18-fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388-95.
9. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases. CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005;237:123-31.
10. Rappeport ED, Loft A, Bertheisen AK, von der Recke P, Larsen PN, Mogensen AM, et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 2007;48:369-78.
11. Sahani DV, Kalva SP, Fischman AJ, Kadavigere R, Blake M, Hahn PF, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 2005;185:239-47.
12. Strauss L, Bostel F, Clorius JH, Raptou E, Wellman H, Georgi P. Single-photon emission computed tomography (SPECT) for assessment of hepatic lesions. J Nucl Med 1982;23:1059-65.
13. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992;16:684-89.
14. Strauss LG, Klippel S, Pan L, Schönleben K, Haberkorn U, Dimitrakopoulou-Strauss A. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging 2007; 34:868-77.
15. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of 68Ga-DOTATOC and 18F-FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115-22.
16. Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Quantitative PET Studies in pretreated melanoma patients: a comparison of 6-18F-fluoro-l-dopa with 18F-FDG and 15O-water using compartment and noncompartment analysis. J Nucl Med 2001;42:248-56.
17. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumours: comparison with 18F-FDG. J Nucl Med 2007;48:1245-50.